XML 26 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
10. SEGMENTS
3 Months Ended 12 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Segment Reporting [Abstract]    
SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

   

The following tables set forth certain information regarding our segments:

 

   Three Months Ended June 30, 
   2017   2016 
Revenues:        
Aethlon  $   $4,635 
ESI        
Total Revenues  $392,073   $4,635 
           
Operating Losses:          
Aethlon  $(1,141,406)  $(1,092,990)
ESI   (18,843)   (38,662)
Total Operating Loss  $(1,160,249)  $(1,131,652)
           
Net Losses:          
Aethlon  $(1,826,708)  $(2,097,887)
ESI   (18,843)   (38,662)
Net Loss Before Non-Controlling Interests  $(1,845,551)  $(2,136,549)
           
Cash:          
Aethlon  $326,464   $1,291,537 
ESI   742    2,722 
Total Cash  $327,206   $1,294,259 
           
Total Assets:          
Aethlon  $492,324   $1,419,226 
ESI   16,827    41,806 
Total Assets  $509,151   $1,461,032 
           
Capital Expenditures:          
Aethlon  $23,705   $1,545 
ESI        
Capital Expenditures  $23,705   $1,545 
           
Depreciation and Amortization:          
Aethlon  $9,326   $5,323 
ESI       4,895 
Total Depreciation and Amortization  $9,326   $10,218 
           
Interest Expense:          
Aethlon  $(188,604)  $(42,167)
ESI        
Total Interest Expense  $(188,604)  $(42,167)

    

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

 

The following tables set forth certain information regarding our segments:

 

   Fiscal Years Ended March 31, 
   2017   2016 
Revenues:        
Aethlon  $392,073   $886,572 
ESI        
Total Revenues  $392,073   $886,572 
           
Operating Losses:          
Aethlon  $(5,945,293)  $(3,953,402)
ESI   (153,064)   (431,432)
Total Operating Loss  $(6,098,357)  $(4,384,834)
           
Net Losses:          
Aethlon  $(7,153,662)  $(4,527,184)
ESI   (153,064)   (431,432)
Net Loss Before Non-Controlling Interests  $(7,306,726)  $(4,958,616)
           
Cash:          
Aethlon  $1,558,667   $2,114,285 
ESI   1,034    9,452 
Total Cash  $1,559,701   $2,123,737 
           
Total Assets:          
Aethlon  $1,698,249   $2,475,686 
ESI   28,119    53,430 
Total Assets  $1,726,368   $2,529,116 
           
Capital Expenditures:          
Aethlon  $16,433   $9,307 
ESI        
Capital Expenditures  $16,433   $9,307 
           
Depreciation and Amortization:          
Aethlon  $22,370   $18,943 
ESI   10,043    19,581 
Total Depreciation and Amortization  $32,413   $38,524 
           
Interest Expense:          
Aethlon  $304,330   $573,782 
ESI        
Total Interest Expense  $304,330   $573,782